THE USEFULNESS OF THE EXISTING GUIDELINES FOR PERFORMANCE OF ENDOMYOCARDIAL BIOPSY IN PATIENTS WITH SUSPECTED MYOCARDITIS AND RELATED OUTCOMES IN A CONTEMPORARY ERA

L Murphy, M McGuckin, G Giblin, A Keogh, B McGovern, A Fabre, J O’Neill, N Mahon, E Joyce. Mater Misericordiae University Hospital, Dublin, Ireland; St Vincent’s University Hospital, Elm Park, Dublin 4, Ireland

Introduction Diagnostic endomyocardial biopsy (EMB) in patients with myocarditis helps to direct therapy and guide prognosis. The original 2007 joint scientific statement provided guideline indications based on unique clinical scenarios, detailing who should undergo this invasive investigation but have not been studied in a contemporary cohort of suspected myocarditis patients.

Purpose To investigate the correlation between the clinical guideline indications for EMB and the presence of a diagnostic biopsy result and associated outcomes in patients with suspected myocarditis in a national quaternary referral center.

Methods All cases of suspected myocarditis referred to the National Advanced Heart Failure and Transplant Center between 2009–2019 were identified through pathological records. A thorough retrospective chart review was then performed on all patients. Outcomes including need for inotrope or mechanical circulatory support (MCS), heart transplantation and in-hospital mortality were recorded.

Results In total, 25 (68% male, mean age of 45 ± 15 years) EMBs were performed for suspected myocarditis between 2009–2019, 64% (n=16) of which demonstrated diagnostic results. Clinical characteristics of those with histologically confirmed myocarditis are represented in figure 1. Regarding pathologic subtypes, 81% (n=13) identified an acute lymphocytic myocarditis, 13% (n=2) giant cell myocarditis and one patient (6.3%) eosinophilic myocarditis. The majority of those with a histologically confirmed myocarditis had a Class I or IIa indication for EMB (n=12, 75%). All patients requiring inotropes and/or MCS (n=9) and/or heart transplant (n=3) were in this group. The remaining 4 patients (25%), of whom three were diagnosed with acute lymphocytic myocarditis and one an immune checkpoint inhibitor (ICI) myocarditis, either met Class IIb criteria (n=2) or would not have been accounted for in this guideline. Four patients (25%) died during the index admission, one of whom was in the latter group (histologically confirmed myocarditis without a 2007 guideline indication).

Conclusions In this National referral sample, 75% of patients with suspected myocarditis had a Class I or IIa indication for EMB, reinforcing the usefulness of these guidelines even in a contemporary era. Further, existing guideline indications appeared to identify a sicker group of patients more frequently requiring inotropes, MCS and/or heart transplant. However, in the contemporary era, 25% of patients had either none or a less well established indication for EMB despite a subsequent confirmed histological diagnosis, including a case of immune checkpoint inhibitor myocarditis, which has emerged since the publication of the 2007 guidelines. This highlights the need for clinical suspicion and correlation outside of accepted clinical scenarios.
Methods Retrospective cohort analysis was performed on all patients admitted to the coronary care unit (CCU) between January 2011 and September 2019. A review of the electronic health records of patients with new or established type 2 DM, who had been admitted with acute coronary syndrome (ACS) or heart failure (HF) as their primary diagnosis code was performed. Discharge prescriptions were analysed to determine which patients had been prescribed a SGLT2 inhibitor. The admission creatinine and estimated glomerular filtration rate (eGFR) for all patients were recorded. eGFR ≥ 60 was used as the eligibility threshold for initiation of treatment with SGLT2 inhibitor as per summary of product characteristics. This data was analysed to determine whether there was a temporal change in prescriptions of this drug class. Statistical analysis was performed using standard Bayesian statistics.

Results There were 6870 patients admitted to the CCU between January 2011 and September 2019. 1054 patients had a diagnosis of type 2 DM and were admitted with ACS or HF. 77 patients were excluded from the study due to incomplete data. Thus, 977 patients were included in the final data set for analysis. There were 54 newly diagnosed diabetics and 923 with established type 2 DM. 865 patients were admitted with ACS and 112 patients with HF. The ratio of male to female was 2.6:1. The mean age of the patient cohort was 65.

There was a total of 40 patients prescribed SGLT2 inhibitors. Prior to the EMPA-Reg study in 2015, there were 4 of 387 eligible patients prescribed SGLT2 inhibitors, compared to 36 of 221 eligible patients thereafter. Chi-square statistic 45.1429 (p <0.00001). Temporal analysis from 2015 to 2019 showed increase in use from 5.5% to 20.5% (figure 1).

Conclusion There was a statistically significant increase in the use of SGLT2 inhibitors since the EMPA-Reg study. Recent published data on the benefits this drug class confers on HF management further strengthens the evidence for this change in practice. The new ESC guidelines were published in September 2019, which we suspect will result in even more widespread use of these drugs.

27 what is the relationship between chronic kidney disease and subsequent events in a coronary heart disease population? a secondary analysis of the EUROASPIRE V data
12 M Coyle, 2C Jennnings, 2G Avalos, 1IW McEvoy. 1School of Medicine, National University of Ireland Galway, Ireland; 2National Institute for Prevention and Cardiovascular Health, Galway, Ireland; 3Department of Medicine, National University of Ireland, Galway Campus, Galway Ireland; 4University of Ireland, Galway Campus, Galway, Ireland, ESC National Coordinator for CVD Prevention, Ireland
10.1136/heartjnl-2020-ICS.27
Introduction Chronic kidney disease (CKD) is an important risk factor for cardiovascular disease (CVD). The EUROASPIRE V study, conducted across 27 European countries (2016–2017), investigated whether the European guidelines on secondary CVD prevention were being met.

Aims The aim of this secondary analysis of the EUROASPIRE V data was to compare the CVD event-rate in those with and without CKD (defined as an eGFR < 60 ml/min/1.73 m²).

Methods A cohort study was conducted of patients who were interviewed between 6–24 months after an index event.